Obesity

Seuraa
Study links prediabetes remission to lower diabetes risk without weight loss

Researchers in Tübingen have found that people with prediabetes can reduce their risk of developing type 2 diabetes by 71% through lifestyle changes that normalize blood sugar levels, even if they do not lose weight. The study emphasizes the role of improved fat distribution over mere weight reduction. This challenges current guidelines focused primarily on shedding pounds.

Scientists discover protein that switches off hunger

05. lokakuuta 2025 Raportoinut AI

Researchers have identified how a protein called MRAP2 regulates hunger by transporting the brain receptor MC4R to the cell surface, enhancing appetite-suppressing signals. This finding, from a study involving institutions in Germany, Canada, and the UK, could lead to new obesity treatments. The work was published in Nature Communications.

End of patent protection for weight loss injections benefits patients

03. lokakuuta 2025 Raportoinut AI

Patent protection for semaglutide in weight loss injections like Ozempic and Wegovy is expiring in Europe. This paves the way for cheaper generics to enter the market and could lower high prices. Patients with obesity stand to benefit from improved access.

Study highlights disparities in obesity care access

04. lokakuuta 2025 Raportoinut AI

A recent analysis reveals significant gaps in obesity treatment for certain demographic groups in the United States. Researchers found that access to care varies widely based on race, income, and location, underscoring ongoing challenges in healthcare equity.

Higher semaglutide dose boosts weight loss in obesity trials

Two phase 3 clinical trials show that a 7.2 mg weekly dose of semaglutide leads to greater weight loss than the approved 2.4 mg dose in adults with obesity, including those with type 2 diabetes. Nearly half of participants on the higher dose lost 20% or more of their body weight over 72 weeks. The results, published in The Lancet Diabetes & Endocrinology, suggest improved metabolic health with a favorable safety profile.